GlassScriptPhysician profile
Lorie Campbell
NPI 1831552728
$1,786.96
in general payments reported to CMS, 2019-2025
26 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $910 · 2023: $245 · 2024: $378 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.88 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $283.92 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.81 | 2022-2023 | Plenvu, Xifaxan, Trulance |
| Lilly USA, LLC | $166.44 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Mirum Pharmaceuticals, INC. | $97.04 | 2022-2024 | Livmarli |
| Amgen INC. | $81.43 | 2022-2024 | Repatha, Otezla, Evenity |
| Daiichi Sankyo INC. | $67.37 | 2022-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $55.83 | 2022-2024 | Linzess |
| Janssen Biotech, INC. | $55.07 | 2022-2023 | Stelara |
| Braintree Laboratories, INC. | $41.39 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.56 | 2022 | |
| Exact Sciences Corporation | $34.63 | 2023-2024 | Cologuard Collection Kit |
| Echosens North America, INC. | $29.83 | 2022 | |
| Azurity Pharmaceuticals, INC. | $29.18 | 2024-2025 | |
| Genzyme Corporation | $28.70 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.77 | 2024 | Veozah |
| Abiomed | $21.03 | 2025 | |
| Ferring Pharmaceuticals INC. | $20.32 | 2022 | |
| Qol Medical, LLC | $19.93 | 2023 | Sucraid |
| Glaxosmithkline, LLC. | $19.24 | 2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $18.91 | 2024 | |
| Supernus Pharmaceuticals, INC. | $18.88 | 2025 | Qelbree |
| Novo Nordisk INC | $17.55 | 2024 | Rybelsus, Ozempic |
| Redhill Biopharma INC. | $15.32 | 2022 | |
| Abbott Laboratories | $14.88 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorie Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.